

## MOPL01 Plenary Session

Plenary Session

**Venue:** Le Grand Amphithéâtre

**Time:** 08:45-10:30

**Co-Chairs:** Chris Beyrer, Johns Hopkins University, United States  
Deborah Birx, The U.S. President's Emergency Plan for AIDS Relief (PEPFAR), United States

### Harnessing the immune system to prevent and control HIV infection

*Y. Lévy, Institut national de la santé et de la recherche médicale (Inserm), France*

### Persons living with HIV: top priority for programmes

*W. El-Sadr, ICAP at Columbia University, United States*

### Adding D to the ABC: putting the drugs in the ABC of prevention

*S. McCormack, University College London (UCL), United Kingdom*

### ViiV Stigma Award

*D. Waterhouse, ViiV Healthcare, United Kingdom*

### Me and My Healthcare Provider

*D. Birx, The U.S. President's Emergency Plan for AIDS Relief (PEPFAR), United States*

## MOAB01 Antiretroviral Therapy - ART: Season One

Oral Abstract Session

**Venue:** Le Grand Amphithéâtre

**Time:** 11:00-12:30

**Co-Chairs:** James Hakim, University of Zimbabwe, Zimbabwe  
Sasisopin Kiertiburanakul, Ramathibodi Hospital, Thailand

### Immunodeficiency at the start of combination antiretroviral therapy in low-, middle- and high-income countries

*N. Anderegg, O. Kirk, for the TeDEA & COHERE collaborations Switzerland*

### ANRS 146 - GeSIDA 7211 OPTIMAL phase III trial: maraviroc plus cART in advanced HIV-1-infected individuals

*Y. Levy, J.-D. Lelièvre, L. Assoumou, E. Aznar, F. Pulido, G. Tambussi, M. Crespo, A. Meybeck, J.-M. Molina, F. Cardon, A. Diallo, C. Delaugerre, R. Lancar, L. Béniguel, D. Costagliola, on behalf of the ANRS 146 - GeSIDA 7211 study group France*

### 48-weeks efficacy of a third-line based on darunavir plus raltegravir regimen in HIV-infected adults who failed second-line protease inhibitor-based regimen in sub-Saharan Africa, ANRS 12269 THILAO study

*R. Moh, A. Benalycherif, D. Gabillard, J. Lecarrou, L. N'guessan, A. Anzian, D. Minta, A. Sawadogo, M. Seydi, J. Drabo, M.-L. Chaix, P.-M. Girard, C. Danel, X. Anglaret, S. Eholié, R. Landman, Thilao Study Group Cote d'Ivoire*

### A phase 3 randomized controlled clinical trial of bicittegravir in a fixed dose combination, B/F/TAF, vs ABC/DTG/3TC in treatment-naïve adults at week 48

*J. Gallant, A. Lazzarin, A. Mills, C. Orkin, D. Podzamczar, P. Tebas, P.-M. Girard, I. Brar, E. Daar, D. Wohl, J. Rockstroh, X. Wei, K. White, H. Martin, E. Quirk, A. Cheng United States*

### Dual therapy with darunavir/ritonavir plus lamivudine for HIV-1 treatment initiation: week 24 results of the randomized ANDES study

*O. Sued, M.I. Figueroa, A. Gun, W. Belloso, D. Cecchini, G. Lopardo, D. Pryluka, M.J. Rolon, V. Fink, S. Perez Lloret, P. Cahn Argentina*

### ACTG A5353: a pilot study of dolutegravir (DTG) + lamivudine (3TC) for initial treatment of HIV-1-infected participants with HIV-1 RNA < 500,000 copies/mL

*B.O. Taiwo, L. Zheng, A.N. Nyaku, A. Stefanescu, P.E. Sax, D. Haas, B. Berzins, C.L. Wallis, K.Y. Smith, B. Ha, C. Godfrey, J. Kumwenda, E. Acosta, B. Sha, C. Van Dam, R.M. Gulick, A5353 Team United States*

## MOAX02 Co-Chairs' Choice

Oral Abstract Session

**Venue:** Blue Amphitheater

**Time:** 11:00-12:30

**Co-Chairs:** Linda-Gail Bekker, Desmond Tutu HIV Centre, South Africa  
Jean-François Delfraissy, Paris 11 University, France

### A randomized controlled trial for the treatment of HIV-associated cryptococcal meningitis in Africa: oral fluconazole plus flucytosine or one week amphotericin-based therapy vs two weeks amphotericin-based therapy. The ACTA Trial

*S. Molloy, C. Kanyama, R. Heyderman, A. Loyse, C. Kouanfack, D. Chanda, S. Mfinanga, E. Temfack, S. Lakhi, S. Lesikari, A. Chan, N. Stone, N. Kalata, N. Karunaharan, K. Gaskell, M. Peirse, J. Ellis, C. Chawinga, S. Lontsi, J.-G. Ndong, P. Bright, D. Lupiya, T. Chen, J. Bradley, J. Adams, C. van der Horst, J.J. van Oosterhout, V. Sini, Y.N. Mapoure, P. Mwaba, T. Bicanic, D. Lalloo, D. Wang, M. Hosseinipour, O. Lortholary, S. Jaffar, T. Harrison, ACTA Trial Study Team United Kingdom*

### Dolutegravir / tenofovir / emtricitabine (DTG/TDF/FTC) started in pregnancy is as safe as efavirenz / tenofovir / emtricitabine (EFV/TDF/FTC) in nationwide birth outcomes surveillance in Botswana

*R. Zash, D. Jacobson, G. Mayondi, M. Diseko, J. Makhema, M. Mmalane, T. Gaolathe, C. Petlo, L. Holmes, M. Essex, S. Lockman, R. Shapiro United States*

### Weekly oral MK-8591 protects male rhesus macaques against repeated low dose intrarectal challenge with SHIVC109P3

*M. Markowitz, A. Gettie, L. St. Bernard, H. Mohri, C.D. Andrews, A. Horowitz, J. Blanchard, B. Grasperge, L. Sun, K.L. Filigrove, D.J. Hazuda, J.A. Grobler United States*

### Substantial progress in confronting the HIV epidemic in Swaziland: first evidence of national impact

*R. Nkambule, H. Nuwagaba-Biribonwoha, Z. Mnisi, T.T. Ao, C. Gimindza, Y.T. Duong, H. Patel, S. Saito, N.M. Philip, K. Brown, C. Draghi, A.C. Voetsch, K. Mabuza, A. Zwane, R. Sahabo, V. Okello, T. Dobbs, B. Parekh, C. Ryan, J. Justman Swaziland*

### Safety and efficacy of long-acting CAB and RPV as two drug IM maintenance therapy: LATTE-2 week 96 results

*J. Eron, D. Margolis, J. Gonzalez-Garcia, H.-J. Stellbrink, Y. Yazdanpanah, D. Podzamczar, T. Lutz, J.B. Angel, G.J. Richmond, B. Clotet, F. Gutierrez, L. Sloan, K.C. Sutton, D. Dorey, K.Y. Smith, P.E. Williams, W.R. Spreen United States*

### Treatment of chronic hepatitis C genotype 1, 2 and 4 in patients with or without HIV and living in Central or West Africa: the TAC ANRS 12311 trial

*K. Lacombe, R. Moh, C. Chazallon, J. Lecarrou, B. Sylla, M. Lemoine, C. Kouanfack, L. Ciaffi, F. Fadiga, N. Rouveau, J. Gozlan, M. Seydi, V. Cissé, C. Danel, P.M. Girard, A. Attia, and the TAC ANRS 12311 study group France*

## MOAX01 Just Do It Yourself: Preferences and Performances of HIV Self-testing

Oral Abstract Session

**Venue:** Bordeaux Amphitheater

**Time:** 11:00-12:30

**Co-Chairs:** Augustine Choko, London School of Hygiene & Tropical Medicine, United Kingdom  
Heidi Van Rooyen, Human Sciences Research Council, South Africa

### Self-testing: an effective means of increasing HIV-testing and status awareness

*A. Moore, T. Cassidi, S.J. Steele, A. Shroufi, N. Ntuli, L. Ndani, C. Metcalf, T. Ellman, E. Goemare, L. Trivino Duran*  
South Africa

**HIV self-testing: feasibility and acceptability of a large scale national service delivered by a community organisation**

*C. James, D. Edwards, W. Harris, M. Brady*  
United Kingdom

**The impact of HIV self-testing among internet-recruited MSM, eSTAMP 2015-2016**

*R.J. MacGowan, P.R. Chavez, C.B. Borkowf, P.S. Sullivan, J.H. Mermin*  
United States

**Feasibility of HIV self-test programming among female sex workers in Zimbabwe**

*S. Mavedzenge, E. Sibanda, J. Dirawo, K. Hatzold, O. Mugurungi, F. Cowan*  
United States

**HIV self-testing among female sex workers in Zambia: a randomized controlled trial**

*M. Chanda, K. Ortblad, M. Mwale, S. Chongo, C. Kanchele, N. Kamungoma, A. Fullem, C. Dunn, L. Barresi, G. Harling, T. Bärnighausen, C. Oldenburg*  
United States

**Performance and usability of INSTI, a blood-based rapid HIV self test for qualitative detection of HIV antibodies in intended use populations in Kenya**

*M. Mwaui, L. Achieng, P. Bwana*  
Kenya

**MOAB02 Children and Adolescents: Issues in the First and Second Decade**

Oral Abstract Session

**Venue:** Havana Amphitheater

**Time:** 11:00-12:30

**Co-Chairs:** Annette Sohn, amfAR, the Foundation for AIDS Research, Thailand  
Moherndran Archary, Nelson R Mandela School of Medicine, South Africa

**Maximizing targeted testing to improve HIV yield among children and adolescents in Rwenzori region, Uganda**

*H. Bitimwine, F. Musiime, P. Ajuna, P. Tumbu, P. Nahiry-Ntege, A. Kekitiinwa*  
Uganda

**Impacts of vitamin D and calcium supplementation on bone mineral density among perinatally HIV-infected adolescents: a 48-week randomized clinical trial**

*T. Sudjaritruk, L. Aурpibul, T. Bunupuradah, S. Kanjanavanit, T. Chotecharoentanan, S. Taejaroenkul, P. Ounchanum, P. Suntarattiwong, T. Puthanakit, CAL-D Study Group*  
Thailand

**Inequality in mortality and access to antiretroviral therapy in adolescents living with perinatally-acquired HIV in sub-Saharan Africa: a Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) cohort collaboration analysis**

*A. Slorove, V. Leroy, A. Judd, CIPHER Global Cohort Collaboration Adolescent Project Team*  
South Africa

**Evaluation of the risk of birth defects among children exposed to raltegravir in utero in the ANRS-French Perinatal Cohort EPF**

*J. Sibuide, J. Warszawski, S. Blanche, O. Dialla, A. Faye, C. Dollfus, L. Mandelbrot, R. Tubiana, for the ANRS-EPF CO1/CO11 Study group*  
France

**High prevalence of respiratory non-tuberculous mycobacteria respiratory infections in children living with HIV in South-East Asia**

*L. Borand, A. de Lauzanne, M. Inghammar, V. Ung, S. Cheng, T.H. Pham, P. Msellati, M. Tejjokem, A.-S. Ouedraogo, S. Godreuil, C. Delacourt, S. Blanche, O. Marcy, ANRS 12229 PAANTHER 01 Study Group*  
Cambodia

**High-risk vaccine-specific HPV infection in HIV-infected and HIV-uninfected, vaccine-naïve Asian female adolescents**

*S. Sricharoenchai, T. Bunupuradah, R. Hansudewechakul, D.L.D. Hanh, D.N.H. Tran, S. Kerr, A. Chalermchockcharoenkit, N. Teeratakulpisarn, J. Achalapong, D.N.Y. Dung, W. Termrungruanglert, S. Chaithongwongwatthana, T. Singtoroj, T. Pankam, N. Phanuphak, A.H. Sohn, K. Chokeyphaibulkit, HPV in Adolescents Study team*

Thailand

**MOSY01 Transgender Populations: Connecting the Dots for Trans Clinical Care Services and HIV Care**

Symposia Session

**Venue:** Maillot Room

**Time:** 11:00-12:30

**Co-Chairs:** Nittaya Phanuphak, Thai Red Cross AIDS Research Centre, Thailand  
Alicia Krüger, Ministry of Health, Brazil

Despite the disproportionate burden of HIV infection facing transgender communities, particularly for transwomen, transgender individuals continue to represent an underserved, highly stigmatized, and under-resourced population in both general clinical care and HIV prevention services. This session, aimed at healthcare providers, including clinicians, nurses and pharmacists, researchers, transgender individuals and community advocates, discusses the issues surrounding care for trans populations who are also affected by HIV.

**Introduction**

**Gender affirmation and HIV care: challenges for linkage to care**

*E. Wilson, San Francisco Department of Health, United States*

**Service integration: mental health and beyond**

*G. Knudson, University of British Columbia, Canada*

**Gender-affirming hormones and antiretroviral therapy: implications on adherence and clinical outcomes**

*A. Radix, Callen-Lorde Community Health Center, United States*

**Connecting trans HIV clinical care and research - using cross cohort analyses to identify long-term complications**

*T. Poteat, Johns Hopkins University, United States*

**Questions and answers**

**Closing remarks**

**MOSY02 Advances in HIV Transmission and Regulation of Replication**

Symposia Session

**Venue:** Room 241

**Time:** 11:00-12:30

**Co-Chairs:** Eric Hunter, Emory University, United States  
Andrea Cimorelli, University of Lyon, France

This symposium focuses on the impact of host genetic and biological variations, viral pre-adaptation and restriction factors on HIV acquisition and replication in both primates and humans. This session provides a brief historical overview, in order to illustrate where we are coming from followed by the latest discoveries in the field to highlight where we stand now, and how these discoveries can help us develop strategies to better limit and counter viral transmission and replication. This symposium is tailored to scientists and clinicians concerned with a deep understanding of HIV pathogenesis and the transmission of the virus.

**Introduction**

**Regulation of HIV infection by viral capsid**

*G. Towers, University College London (UCL), United Kingdom*

**Impact of pre-adapted HIV transmission**

*P. Goepfert, University of Alabama, United States*

**Restriction factors**

*M. Benkirane, Institute of Human Genetics - CNRS, France*

**Permissibility factors for HIV replication during mucosal transmission**

*T. Hope, Northwestern University, United States*

**Lessons from non-human primates**

M.Müller-Trutwin, Institut Pasteur, France

## Questions and answers

### Closing remarks

#### MOSY03 Topical Agents for PrEP: As Good as Systemic PrEP?

Symposia Session

**Venue:** Room 242

**Time:** 11:00-12:30

**Co-Chairs:** Raphael Landovitz, Center for Clinical AIDS Research & Education, United States  
Jared Baeten, University of Washington, United States

Daily use of PrEP has proved to be a very effective tool in preventing HIV when taken consistently, with many countries adopting the new WHO guidelines on oral daily PrEP with emtricitabine/tenofovir. However, many studies have cited an inability to take a daily pill by some sub-populations as contributing to low adherence among these groups. Additionally, potential toxicity with systemic PrEP may also affect PrEP efficacy. As a result, a wide range of dosage forms of topical PrEP agents are needed as PrEP as a prevention tool evolves. This symposium, aimed at researchers, clinicians and healthcare providers, community workers and people using PrEP, explores the pharmacology, different delivery forms and adherence/acceptability challenges of topical PrEP.

#### Introduction

R.Landovitz, Center for Clinical AIDS Research & Education, United States

#### Does pharmacology support topical PrEP?

A.Kashuba, University of North Carolina, United States

#### Lessons learnt from tenofovir vaginal gel studies

S.Abdool Karim, Centre for the AIDS Programme of Research in South Africa (CAPRISA), South Africa

#### Intra-vaginal rings for PrEP: what are the future prospects?

A.Nel, International Partnership for Microbicides (IPM), United States

#### Rectal gels for PrEP: are they an option?

I.McGowan, University of Pittsburgh, United States

#### Adherence and acceptability challenges with topical PrEP

J.Haberer, Massachusetts General Hospital (MGH), United States

## Questions and answers

### Closing remarks

J.Baeten, University of Washington, United States

#### MOSY04 Translational Vaccinology

Symposia Session

**Venue:** Room 251

**Time:** 11:00-12:30

**Co-Chairs:** Tetsuro Matano, AIDS Research Center National Institute of Infectious Diseases, Japan  
Pascal Poignard, CHU Grenoble Alpes, France

This session focuses on the critical role of vaccine development in the response to HIV. This session addresses all scientists and clinicians concerned with the genesis of novel HIV vaccine candidates towards their efficacy in clinical trials. Speakers will discuss the ongoing need to get an effective vaccine to win the war against HIV in the current ART landscape. Additionally, the latest discoveries with regards to vaccine design and trials in humans will highlight where we stand today in our endeavour to develop a successful HIV vaccine.

#### Introduction

#### How close are we to the perfect vaccine?

G.Gray, South African Medical Research Council, South Africa

#### Progress in antibody-mediated preventive vaccine strategies

H.Schuitemaker, Janssen Vaccines & Prevention, Netherlands

#### VAC -3S: a gp41 therapeutical vaccine increasing CD4 cells

in patients under HART

P.Debré, CIMI-Paris, France

#### Experimental medicine clinical trials of promising new HIV candidates

R.Shattock, Imperial College London, United Kingdom

#### Conserved epitope based vaccines

T.Hanke, University of Oxford, United Kingdom

## Moderated discussion

### Closing remarks

#### MOPDB01 Comorbidities in an Ageing Era

Poster Discussion Session

**Venue:** Maillot Room

**Time:** 13:00-14:00

**Co-Chairs:** Anne Simon, Hôpital Pitié-Salpêtrière, France  
Jose M Gatell, University of Barcelona, Spain

#### More and earlier cardiovascular events (CVE) and shorter overall survival (OS) in HIV-positive patients (HIV+) compared to the general population differ by sex

S.Esser, M. Arendt, C. Schulze, V. Holzendorf, N.H. Brockmeyer, K.-H. Jöckel, R. Erbel, N. Reinsch, HIV HEART Study Group and Heinz Nixdorf Recall Investigative Group Germany

#### Incidence of renal Fanconi syndrome in patients taking antiretroviral therapy including tenofovir disoproxyl fumarate

N.A. Medland, E.P.F. Chow, R.G. Walker, M. Chen, T.H.R. Read, C.K. Fairley Australia

#### Higher HDL, better brain? Higher HDL cholesterol is associated with better cognition in a cohort of older persons living with HIV infection

A. Mankanjuola, K. Wu, K. Tassiopoulos, B. Berzins, A. Ogunniyi, K. Robertson, B. Taiwo, F. Chow United States

#### The combination of Tai Chi, cognitive behavioral therapy and motivational text messaging improves physical function, reduces substance use and improves pain in older HIV-infected adults

J.E. Lake, M.C. Reid, S.G. Edwards, A. Kuerbis, J. Candelario, D. Liao, L. Tang, A.A. Moore, for the STOP PAIN Study United States

#### Capacity to screen and manage mental health disorders at HIV treatment sites in low- and middle-income countries

A. Parcesepe, C. Mugglin, M. Egger, F. Nalugoda, C. Bernard, E. Yuniastuti, S. Duda, C. William Wester, D. Nash, IeDEA Network Collaboration United States

#### MOPDC01 Anti-virals and Pregnancy

Poster Discussion Session

**Venue:** Room 241

**Time:** 13:00-14:00

**Co-Chairs:** Laurent Mandelbrot, Uni, France  
Laura Guay, Elizabeth Glaser Pediatric AIDS Foundation, United States

#### Methods of gestational age (GA) assessment influence the observed association between ART exposure and preterm delivery (PTD): a prospective study in Cape Town, South Africa

T. Malaba, M.-L. Newell, H. Madlala, A. Perez, C. Gray, L. Myer, for the PIMS Study South Africa

#### Pregnancy outcomes and infant survival in the era of universal HAART in Africa: the POISE study

*S. Dadabhai, L. Gadama, R. Chamanga, R. Kawalazira, C. Katumbi, D. Dula, I. Singini, L. Degnan, M. Kamanga, B. Lau, T.E. Taha Malawi*

## **ARV drug concentrations in breastmilk, viral load, and HIV transmission to the infant**

*N. Davis, A. Corbett, J. Kaulen, J. Nelson, C. Chasela, D. Sichali, M. Hudgens, W. Miller, D. Jamieson, A. Kourtis, BAN study team United States*

## **Stillbirth in HIV-infected women delivering in UK/Ireland between 2007 and 2015**

*G. Favaro, H. Bailey, H. Peters, K. Francis, A. Horn, R. Sconza, P. Tookey, C. Thorne, National Study of HIV in Pregnancy and Childhood (NSHPC) United Kingdom*

## **Usefulness of HBV rapid tests to identify pregnant women at high-risk of HBV mother to child transmission: the pilot ANRS 12328 study in Cambodia**

*O. Segeal, D. N'Diaye, S. Prak, W. Khamduang, J. Nouhin, M. Ek, K. Chim, S. Hout, A.-M. Roque-Afonso, P. Piola, N. Ngo-Giang-Huong, F. Rouet Cambodia*

## **Breast milk dapivirine pharmacokinetics and estimated infant exposure during dapivirine intravaginal ring use among lactating women**

*L. Noquchi, R. Beigi, J. Biggio, M. Marzinke, C. Kelly, R. Scheckter, K. Bunge, J. Piper, S. Hillier, A. Nel, C. Hendrix United States*

### **MOPDD01 Getting on with #Adolescents**

Poster Discussion Session

**Venue:** Room 242

**Time:** 13:00-14:00

**Co-Chairs:** Annette Sohn, amfAR, the Foundation for AIDS Research, Thailand  
Chewe Luo, UNICEF, United States

### **HIV treatment and care services for adolescents: a situational analysis of 218 facilities in 23 sub-Saharan African countries**

*D. Mark, A. Armstrong, C. Andrade, M. Penazzato, L. Hatane, L. Taing, T. Runciman, N. Sugandhi, J. Ferguson South Africa*

### **Factors associated with viral suppression among adolescents living with HIV in Cambodia**

*S. Yi, C. Ngin, S. Tuot, P. Chhoun, K. Pal, S. Sau, K. Chhim, S.C. Choub, G. Mburu, P. Ly Cambodia*

### **Evaluating the implementation and impact of the adolescent package of care at health facilities in former Nyanza province, Kenya**

*M. Mburu, P. Ongwen, M. Guze, N. Okoko, S.B. Shade, C. Blat, J. Kadima, J.P. Otieno, N. Tuma, W. Muriu, E.A. Bukusi, C.R. Cohen, H.T. Wolf Kenya*

### **Economic context and HIV vulnerability in adolescents and young adults living in urban slums in Kenya: a qualitative analysis-based on scarcity theory**

*L. Jennings, M. Muthai, S. Linnemayr, A. Trujillo, M. Mak'anyengo, B. Montgomery, D. Kerrigan United States*

### **The effectiveness and cost-effectiveness of community-based support for adolescents receiving antiretroviral treatment in South Africa**

*G. Fatti, N. Shaikh, O. Oyebanji, F. Chirowa, D. Jackson, A. Goga, T. Magubu, J.B. Nachega, B. Eley, A. Grimwood South Africa*

### **HIV risk behavior, risk perception and experiences in accessing HIV and sexual reproductive health (SRH) services among adolescent key populations in Kenya: a situational analysis**

*A. Ikah, R. Kimathi, M. Kiragu, S. Njenga, M. Mireku, M. Muthare, G. Ombui, J. Kyongo, R. Karuga, E. Gitau, U. Gilbert, H. Musyoki, L. Digolo, W. Mukoma, L. Otiso Kenya*

### **MOPDA01 Getting to the HAART of Immune Activation**

Poster Discussion Session

**Venue:** Room 251

**Time:** 13:00-14:00

**Co-Chairs:** Michaela Müller-Trutwin, Institut Pasteur, France  
Michael Lederman, University Hospital Cleveland, United States

### **A higher fraction of drug resistant proviruses express unspliced HIV RNA during ART compared to the archival wild-type proviruses that comprise the HIV-1 reservoir**

*A. Musick, J. Spindler, M. Sobolewski, M. Bale, B. Keele, W. Shao, A. Wiegand, S. Hughes, J. Mellors, J. Coffin, F. Maldarelli, M. Kearney United States*

### **Evidence of production of HIV-1 proteins from 'defective' HIV-1 proviruses in vivo: implication for persistent immune activation and HIV-1 pathogenesis**

*H. Imamichi, M. Smith, A. Pau, C.A. Rehm, M. Catalfamo, H.C. Lane United States*

### **HIV reservoirs in the brain and association with sex and neurocognition**

*M.F. Oliveira, M. Nakazawa, A. Vitomirov, M. Zhao, B. Gouaux, D. Moore, R. Ellis, D. Smith, S. Gianella United States*

### **Monocyte-derived reactive oxygen species impair CD4+ T cell restoration in HIV-1 patients under therapy**

*M. Younas, Y.-L. Lin, S. Gimenez, P. Portalès, M. Morchikh, D. Maiorano, J. Reynes, P. Pasero, C. Psomas, P. Corbeau France*

### **HIV-1-mediated induction of Hypoxia Inducible Factor-1 alpha activity in CD4+ T cells modifies immunometabolic phenotype and decreases cell survival**

*G.A. Duette, J. Rubione, P. Pereyra Gerber, F. Erra Diaz, A. Varese, C. Palmer, M. Ostrowski Argentina*

### **Toll-like receptor activation modulates inflammation and HIV-1 infection in the female reproductive tract (FEMINIVI study)**

*F.D. Benjelloun, H. Quillay, C. Cannou, R. Marlin, Y. Madec, H. Fernandez, F. Chrétien, R. Le Grand, F. Barré-Sinoussi, M.-T. Nugeyre, E. Menu France*

### **MOSS01 Challenges and Opportunities in HIV Science**

Special Session

**Venue:** Le Grand Amphithéâtre

**Time:** 13:00-14:00

**Co-Chairs:** Marijke Wijnroks, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland  
Agnes Buzyn, Minister of Solidarity and Health, France

### **Sustained ART-free HIV remission: opportunities and obstacles**

*A. Fauci, National Institutes of Health (NIH), United States*

### **Gene therapy: challenges to face for patient's benefit**

*M. Cavazzana, Hospital Necker, France*

### **MOWS01 How to Write and Submit a Conference Abstract**

Workshop

**Venue:** Room 241

**Time:** 14:30-16:00

**Co-Facilitators:** Marlène Bras, Journal of the International AIDS Society, Switzerland  
Elisa de Castro Alvarez, Journal of the International AIDS Society, Switzerland



Attending conferences is a tremendous opportunity to present research, exchange ideas and discuss with peers. Having one's abstract selected is a major determinant to, not only attending but, participating at the conference. However, writing a conference abstract can be a challenge. By the end of this workshop, participants will know how to write and submit a well-written conference abstract and increase chances of acceptance. The main part of the workshop covers the practical aspects of writing an abstract, focusing on its structure and the content required in each section. The workshop also provides key take-home messages and offers examples to illustrate both good practice and common mistakes to avoid. Short exercises are used to enhance the learning experience, using audience participation and comprehensive handouts. In addition, participants learn the formal requirements that need to be met and how their abstracts are reviewed, scored and selected by the conference.

## Welcome and Introduction

*M. Bras, Journal of the International AIDS Society, Switzerland*

## Abstract writing

*M. Bras, Journal of the International AIDS Society, Switzerland;*  
*E. de Castro Alvarez, Journal of the International AIDS Society, Switzerland*

## Submission and review

*M. Bras, Journal of the International AIDS Society, Switzerland*

## Closing, Q&A

### **MOWS02 HIV Cure in Men and Women: From Mechanisms of HIV Latency and Persistence to Potential Therapeutic Strategies**

Workshop

**Venue:** Room 242

**Time:** 14:30-17:00

**Co-Facilitators:** Jintanat Ananworanich, US Military HIV Research Program (MHRP), United States  
Sharon Lewin, The Peter Doherty Institute for Infection and Immunity, Australia

This session, targeted towards a mixed audience of basic scientists, clinical researchers and patient representatives, covers recent findings on HIV latency and persistence and on novel therapeutic strategies to achieve HIV sustainable remission both in men and women. Participants will hear about the latest developments in our knowledge of HIV reservoirs and of mechanistic pathways of latency. The question of biological factors, which could produce sex-based differences in the response to HIV cure strategies, is also addressed. The participants can also learn about novel interventions based on broadly neutralizing antibodies or on potential similarities between cancer and HIV persistence through a short report of the pre-conference forum on HIV cure and cancer.

## Introduction

### Silencing pathways of HIV expression

*O. Rohr, Université de Strasbourg, France*

### New cellular reservoirs

*S. Suzu, Kumamoto University, Japan*

### Potential role of bNAbs in HIV cure

*M. Nussenzweig, The Rockefeller University, United States*

### Implication of sex-based differences in HIV cure

*M. Addo, Universitätsklinikum Hamburg-Eppendorf (UKE), Germany*

### Brief report of the pre-conference forum on HIV cure and cancer

*N. Chomont, University of Montreal, Canada*

## Moderated discussion

## Closing remarks

### **MOWS03 Residual Disease and Immune Activation/Inflammation on ART**

Workshop

**Venue:** Room 251

**Time:** 14:30-17:00

**Co-Facilitators:** Daniel Douek, National Institutes of Health (NIH), United States  
Sara Gianella, University of California San Diego (UCSD), United States

This workshop focuses on the role of persistent immune activation and inflammation in the residual disease of HIV-positive patients receiving ART, from the role of the microbiome to interventions to reduce systemic immune activation, immune ageing and co-morbidities in HIV-positive individuals. Participants at this workshop can learn about issues in confounders and the choice of appropriate controls that are critical to trace the true effect of HIV infection on immune activation and inflammation. This workshop is aimed at scientists and clinicians concerned with a deep understanding of HIV pathogenesis and long term care of treated patients. It provides an historical overview of where we started, through to the latest discoveries that define where we are today, and how these discoveries enable improvements of clinical follow-up and survival for patients.

## Introduction

*S. Gianella, University of California San Diego (UCSD), United States*

### Confounding factors and choice of controls in studies of immune activation and inflammation

*C. Sabin, University College London (UCL), United Kingdom*

### Role of microbiome and virome and change in mucosal immunity

*D. Kwon, Ragon Institute of MGH, MIT and Harvard, United States*

### Immune ageing and viral co-factors

*P. Hunt, University of California, San Francisco (UCSF), United States*

### Inflammatory markers and disease progression in non-human primates

*R. Le Grand, Service Immunologie des Infections Virales et des Maladies Auto-immunes (IMVA), France*

### Inflammation markers and the risk of non-AIDS events

*L. Wittkop, Bordeaux Population Health, France*

### Interventions to reduce immune activation

*O. Lambotte, Paris-Sud University Hospital, France*

## Round table on markers and interventions

## Closing remarks

### **MOAB03 HIV and the Liver: Co-Infection and Complications**

Oral Abstract Session

**Venue:** Bordeaux Amphitheater

**Time:** 14:30-16:00

**Co-Chairs:** Anchalee Avihingsanon, The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thailand  
Estevão Nunes, Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Brazil

### Hepatitis C care cascade for people living with HIV in the country of Georgia

*N. Chkhartishvili, A. Abutidze, N. Bolokadze, O. Chokoshvili, N. Dvali, L. Sharvadze, T. Tsertsvadze Georgia*

### Trends in cause-specific mortality in HIV-hepatitis C (HCV) co-infected patients in Canada (2003-2016): early impact of HCV therapy

*N. Kronfli, S.R. Bhatnagar, M. Hull, E. Moodie, C. Cooper, N. Pick, S. Walmsley, M.-L. Vachon, V. Martel-LeFerre, J. Gill, M. Klein, on behalf of the Canadian Co-Infection Cohort Investigators Canada*

### Efficacy and safety of glecaprevir/pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: the EXPEDITION-2 study

J. Rockstroh, K. Lacombe, R. Viani, C. Orkin, D. Wyles, A. Luetkemeyer, R. Soto-Malave, R. Flisiak, S. Bhagani, K. Sherman, P. Ruane, J. Sasadeusz, J. Slim, Z. Zhang, T. Ng, R. Trinh, M. Sulkowski  
France

**Metabolic syndrome and obesity are the cornerstones of liver fibrosis in HIV-monoinfected patients: results of the METAFIB study**

M. Lemoine, K. Lacombe, J.-P. Bastard, M. Sebire, L. Fonquernie, N. Valin, S. Fellahi, J. Capeau, P.-M. Girard, J.-L. Meynard  
United Kingdom

**Predictor factors associated with liver fibrosis and steatosis by transient elastography in HIV-monoinfected patients under long-term combined antiretroviral therapy: the PROSPEC-HIV study**

H. Perazzo Pedrosa Barbosa, S. Cardoso, C. Yanavich, J.C. Soares, J. Fittipaldi, M. Morata, C. Cardoso, P. Simplicio, C. De Almeida, V. Veloso, B. Grinsztejn  
Brazil

**MOAA01 Hide and Seek: Biology of Reservoirs**

Oral Abstract Session

**Venue: Havana Amphitheater**

**Time: 14:30-16:00**

**Co-Chairs:** Una O'Doherty, University of Pennsylvania, United States  
Véronique Avettand-Fenoel, Université Paris Descartes EA 7327, France

**Assessing individual viral reactivations of the latent reservoir using a novel barcoded virus**

C. Fennessey, M. Pinkevych, T. Immonen, C. Camus, G. Del Prete, J. Estes, J. Lifson, M. Davenport, B. Keele  
United States

**Accumulation and persistence of deleted HIV proviruses following prolonged ART**

E. Anderson, S. Hill, J. Bell, F. Simonetti, C. Rehm, S. Jones, R. Gorelick, J. Coffin, F. Maldarelli  
United States

**A subset of extreme HIV controllers is characterized by a small HIV blood reservoir and a weak T cell activation level**

E. Canoui, C. Lecroux, V. Avettand-Fenoël, M. Goussset, C. Rouzioux, A. Saez-Cirion, L. Meyer, F. Boufassa, O. Lambotte, N. Noel, ANRS CO21 CODEX Study Group  
France

**HIV integration sites in CD4 T cells from virally suppressed individuals show clonal expansion but no preferential location in oncogenes**

J. Symons, A. Chopra, S. Leary, D. Cooper, J.L. Anderson, J.J. Chang, J. McMahon, S.G. Deeks, S. Mallal, P.U. Cameron, S.R. Lewin  
Australia

**The impact of treatment duration on defective and expanded identical HIV genomes in T cell subsets from peripheral blood and tissues**

E. Lee, S. von Stockenström, V. Morcilla, L. Odevall, B. Hiener, W. Show, W. Hartogensis, P. Bacchetti, J. Milush, T. Liegler, E. Sinclair, H. Hatano, R. Hoh, M. Somsouk, P. Hunt, E. Boritz, D. Douek, R. Fromentin, N. Chomont, S.G. Deeks, F.M. Hecht, S. Palmer  
Australia

**Enrichment of the HIV reservoir in CD32+ CD4 T cells occurs early and is closely associated with immune checkpoint receptor expression**

G.E. Martin, M. Pace, J.P. Thornhill, C. Phetsouphanh, E. Hopkins, J. Meyerowitz, N. Nwokolo, J. Fox, C. Willberg, P. Klenerman, S. Fidler, J. Frater, CHERUB Investigators  
United Kingdom

**MOAD01 What's Different about Differentiated Care and Service Delivery?**

Oral Abstract Session

**Venue: Maillot Room**

**Time: 14:30-16:00**

**Co-Chairs:** Wafaa El-Sadr, ICAP at Columbia University, United States  
Tsitsi Apollo, Zimbabwe Ministry of Health and Child Welfare, Zimbabwe

**Readiness for antiretroviral therapy: implications for linking HIV-infected individuals to care and treatment**

B. Maughan-Brown, P. Smith, C. Kuo, A. Harrison, M. Lurie, L.-G. Bekker, O. Galárraga  
South Africa

**Factors associated with loss to follow-up in a primary healthcare HIV clinic practising test and treat**

J. Kiwanuka, N. Kiwanuka, F. Matovu Kiweewa, J. Gonzalez Perez, J. Kitonsa, J. Waia Mukulu  
Uganda

**Pilot study of a multi-pronged intervention using social norms and priming to improve adherence to antiretroviral therapy and retention in care among adults living with HIV in Tanzania**

S. McCoy, C. Fahey, A. Rao, N. Kapologwe, P. Njau, S. Bautista-Arredondo  
United States

**Multi-month refills of antiretroviral drugs for stable patients in Malawi: assessing accuracy in the application of eligibility criteria at the health facility level**

M. Prust, C. Banda, R. Nyirenda, F. Chimbwandira, T. Kalua, A. Jahn, M. Eliya, K. Callahan, P. Ehrenkranz, M. Prescott, E. McCarthy, E. Tagar, A. Gunda  
United States

**Multi-month prescription of antiretroviral therapy and its feasibility: experiences from the Baylor International Pediatric AIDS initiative (BIPAI) in six southern African countries**

M. Kim, R.S. Wanless, S. Ahmed, J. Mhango, D. Damba, A. Kayabu, M. Chodota, S. Dlamini, N. Chidah, M. Mokhali, N. Calles, A. Amzel, R. Golin, E.J. Abrams  
Malawi

**Retention in community versus clinic-based adherence clubs for stable ART patients in South Africa: 24 month final outcomes from a randomized controlled trial**

C. Hanrahan, S. Schwartz, V. Keyser, M. Mudavanhu, N. West, L. Mutunga, J. Steingo, J. Bassett, A. Van Rie  
United States

**MOSY05 Fast-Track Cities: Ending AIDS in High HIV Burden Cities and Municipalities by 2030**

Symposia Session

**Venue: Le Grand Amphithéâtre**

**Time: 14:30-16:00**

**Co-Chairs:** José M. Zuniga, International Association of Providers of AIDS Care, United States  
Praphan Phanuphak, Thai Red Cross AIDS Research Centre, Thailand

To achieve the Sustainable Development Goal of ending the AIDS epidemic as a public health threat by 2030, high HIV burden cities and municipalities must attain the United Nations' 90-90-90 targets for HIV treatment by 2020 and reach ambitious milestones for preventing new HIV infections and addressing barriers to accessing and utilizing HIV services, such as stigma and discrimination. Since World AIDS Day 2014, more than 200 Fast-track Cities around the world have committed to accelerate and scale up their AIDS responses. Many cities and municipalities have made significant progress, which health department and clinician representatives from Amsterdam, Atlanta, Nairobi, Bangkok, and São Paulo highlight during this session. Among the topics covered during the session are standardized measurement of monitoring of the initiative's targets, data-driven HIV care continuum optimization, and addressing barriers to HIV service utilization, including stigma and discrimination.

**Opening remarks**

**Fast-Track Cities – Ending AIDS within an urban context by 2030**

M. Sidibe, UNAIDS, Switzerland

**Towards an AIDS-free Paris – A Fast-Track City's commitment**

B. Jomier, Mairie de Paris, France

**HIV care continuum measurement/monitoring: São Paulo's lessons learned**

E. Kallás, University of São Paulo, Brazil

**Nairobi's strategy: a data-driven response to focus HIV resources**

T. Ogara, Nairobi City County, Kenya

## **Closing the gaps: lessons learned in Amsterdam's success in reaching 90-90-90**

*M.Prins, Academic Medical Centre (AMC), University of Amsterdam, Netherlands*

## **Getting to zero San Francisco: the power of collective impact**

*S.Buchbinder, Bridge HIV, United States*

## **Questions and answers**

## **Closing remarks**

### **MOSY06 HIV in Migrant Communities**

Symposia Session

**Venue:** Blue Amphitheater

**Time:** 14:30-16:00

**Co-Chairs:** Sophie Abgrall, Hôpital Avicennes, France  
Myriam Dieleman, Observatoire du Sida et des Sexualités, Belgium

Migrant communities coming from high-prevalence countries represent a key population in the HIV epidemic. Recent studies have shown that transmission within migrant communities occurs within both host countries and the country of origin; with migrant communities often exhibiting higher sexual risk behaviour and more likely to choose HIV-positive partners. Within a broader context of sexual risk-taking and human rights, this multi-perspective session discusses the issues pertaining to migrants and their role in the HIV epidemic. Aimed at researchers, physicians, policymakers, programme managers and community advocates, this symposia session presents new research and data around migrants living with HIV.

#### **Introduction**

#### **Which rights violations do we observe?**

*C.Izambert, AIDES, France*

#### **Impact of hardship on sexual risk and HIV infection among sub-Saharan migrants living in France**

*A.Desgrées du Lou, Institut de la Recherche pour le Développement Le Sextant, France*

#### **The role of migrant-related stressors**

*L.Michalopoulos, The Columbia School of Social Work, United States*

#### **Additional HIV-related sexual risks among migrants living in the UK**

*V.Delpech, Public Health England, United Kingdom*

#### **Access and response to ART among migrants**

*J.del Amo, The Institute of Health Carlos III, Spain*

#### **Moderated discussion**

#### **Closing remarks**

### **MOWS04 mHealth and the Global HIV Response: Harnessing the Promise of Mobile Technologies for Effective Programme Implementation**

Workshop

**Venue:** Room 241

**Time:** 16:30-18:00

**Co-Facilitators:** Solange Baptiste, International Treatment Preparedness Coalition (ITPC), United States  
Tsitsi Apollo, Zimbabwe Ministry of Health and Child Welfare, Zimbabwe

This session addresses mobile health (mHealth) technologies and social media platforms that are underused to support HIV prevention, increase access to HIV care, decrease healthcare costs, and empower users from science, community, and policy perspectives. mHealth applications can collect community and clinical health data to monitor progress towards 90-90-90; deliver timely healthcare information to practitioners, researchers, and patients; motivate HIV prevention behaviours and use of prevention tools; support medication adherence; and deliver care in real-time via mobile telemedicine. mHealth technology could profoundly alter the way healthcare is delivered, received, and financed. mHealth wallets can store mobile money to pre-pay HIV-related expenses not covered by national programmes, reducing the immediate impact of unexpected out-of-pocket expenses, increasing transparency and trust, and attracting increased investment into healthcare. In this workshop tailored for policy makers, programme implementers, and care providers, participants can learn about best practices in implementing and evaluating novel mHealth strategies.

#### **Introduction**

#### **Review of mHealth evidence: what we know, what we don't know**

*R.Lester, University of British Columbia, Canada*

#### **mHealth tools for antiretroviral HIV prevention and treatment medication monitoring**

*J.Haberer, Massachusetts General Hospital (MGH), United States*

#### **Mobile health wallets in HIV care: what is the impact?**

*M.Olulo, PharmAccess Foundation, Kenya*

#### **mHealth interventions for ensuring effective Prevention of Mother to Child Transmission**

*G.John-Stewart, University of Washington, United States*

#### **Interactive panel discussion**

#### **Closing remarks**

### **MOAD02 Unlocking the Epidemic with Key Populations**

Oral Abstract Session

**Venue:** Bordeaux Amphitheater

**Time:** 16:30-18:00

**Co-Chairs:** Frederick Altice, Yale University, United States  
Margaret Hellard, Burnet Institute, Australia

#### **Why don't key populations access HIV counselling and testing centres in Nepal? Findings based on national surveillance survey**

*R.Shrestha, S. Phillip, H.D. Shewade, B. Ojha, K. Badal, B.B. Rawal, K. Deuba  
Nepal*

#### **Feasibility and acceptability of immediate ART initiation in MSM in West Africa (CohMSM ANRS 12324 - Expertise France)**

*C. Couderc, T.T.E. Dah, F. Diallo, M.J.-B. Kouamé, R.M.K. Agboyibor, A. Bernier, M. Peeters, E. Mensah, N. Meda, C. Anoma, B. Dembélé Keita, B. Spire, C. Laurent, CohMSM Study Group  
Burkina Faso*

#### **Don't get lost: how peer navigation can link HIV-positive key populations to care and treatment and re-engage those lost to follow-up**

*T. Lillie, S. Nemande, H. Gbais, S. Kersten, D. Levitt, F. Ndonko  
Cameroon*

#### **HIV treatment cascade analysis for people who inject drugs in Ukraine: identifying the correlates of continuum**

*K. Dumchev, O. Varetska, T. Salyuk, C. Vitek  
Ukraine*

#### **Effectiveness of comprehensive HIV and stimulant use prevention intervention with Cambodian female entertainment and sex workers**

*K. Page, A. Carrico, E. Stein, J. Evans, M. Sokunny, S. Ngak, C. Sophal, Y. Neak, L. Maher, C. McCulloch  
United States*

**Viral suppression at the first integrated methadone and antiretroviral therapy program for people who inject drugs in sub-Saharan Africa**

*B.H. Lambdin, S. Hassan, D. Mushi, A. Cooke, J. Mbwambo  
United States*

**MOAA02 Kill Me or Neutralize Me**

Oral Abstract Session

**Venue:** Havana Amphitheater

**Time:** 16:30-18:00

**Co-Chairs:** Christiane Moog, University of Strasbourg, France  
Clive M Gray, University of Cape Town, South Africa

MOAA

**Sequential receptor-induced conformational states of native membrane-embedded HIV-1 Env**

*B. Ivan, N. Friedrich, Z. Sun, A. Trkola  
Switzerland*

**Optimized Env trimer immunization parameters amplify onset, magnitude and consistency of autologous Tier 2 neutralizing antibody development in nonhuman primates**

*M. Pauthner, C. Havenar-Daughton, D. Sok, J. Nkolola, R. Bastidas, A. Boopathy, D. Carnathan, A. Chandrashekar, K. Cirelli, C. Cottrell, A. Eroshkin, J. Guenaga, D. Kulp, J. Liu, L. McCoy, G. Ozorowski, K. Post, S. Sharma, J. Steichen, S. de Taeye, T. Tokatlian, A. Torrents de la Peña, S. Butera, C. LaBranche, D. Montefiori, G. Silvestri, I. Wilson, D. Irvine, R. Sanders, W. Schief, A. Ward, R. Wyatt, D. Barouch, S. Crotty, D. Burton  
United States*

**Germinal centers monitored by lymph node fine needle aspirates correlate with and predict HIV Tier 2 neutralizing antibody responses after HIV trimer immunization**

*C. Havenar-Daughton, D. Carnathan, M. Pauthner, J. Liu, J. Nkolola, A. Torrents de la Peña, B. Briney, S. Reiss, J. Wood, K. Kaushik, K. Le, D. Sok, M. Van Gils, S. Kasturi, B. Pulendran, R. Sanders, R. Wyatt, A. Ward, W. Schief, G. Seumois, G. Silvestri, D. Barouch, D. Burton, S. Crotty  
United States*

**Rapid elicitation of broadly neutralizing antibodies to HIV by immunization in cows**

*D. Sok, K. Le, M. Vadnais, K. Saye-Francisco, L. Kong, R. Stanfield, J. Jardine, J. Ruiz, A. Ramos, C.-H. Liang, P. Chen, M. Criscitiello, M. Waithaka, I. Wilson, V. Smider, D. Burton  
United States*

**Killing of HIV-1-infected cells by neutralizing antibodies**

*T. Bruel, F. Guivel Benhassine, V. Lorin, F. Baleux, H. Lortat Jacob, K. Bourdic, N. Noel, O. Lambotte, H. Mouquet, O. Schwartz  
France*

**Allosteric regulation in human anti-HIV-1 Env ADCC-mediating antibodies upon immune complex (IC) formation enhances the binding to FcγRs for the activation of cytotoxicity against HIV-1 virus**

*C. Orlandi, D. Deredge, K. Ray, N. Gohain, W. Tolbert, M. Pazgier, A. Devico, P. Wintrobe, G. Lewis  
United States*

**MOAB04 Tuberculosis in a Time of HIV**

Oral Abstract Session

**Venue:** Maillot Room

**Time:** 16:30-18:00

**Co-Chairs:** Robin Wood, The Desmond Tutu HIV Centre, South Africa  
Diane Havlir, University of California, United States

**Introductory remarks**

*M. Wijnroks, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland*

**Gaps and opportunities in policy and practice in 20 countries with the highest burden of HIV-associated TB**

*A. Baddeley, M. Doherty, A. Kanchar, Y. Hamada, H. Getahun  
WHO*

**Genomic epidemiology of extensively drug-resistant tuberculosis in KwaZulu-Natal, South Africa: demographic expansion and genetic determinants of epidemiologic success in a high HIV prevalence setting**

*T.S. Brown, S.-O. Kolokotronis, S.C. Auld, S. Omar, A. Narechania, N.S. Shah, K.N. Nelson, N. Ismail, B.N. Kreiswirth, J.C.M. Brust, P. Moodley, N.R. Gandhi, B. Mathema  
United States*

**Incidence of tuberculosis in the first year of antiretroviral treatment in West-African HIV-infected adults**

*B. Tchakounte Youngui, P. Coffie, E. Messou, A. Poda, L. Fortes Déguénonvo, D. Haverlander, A. Minga, E. Balestre, F. Dabis, O. Marcy  
France*

**Time to treatment initiation for drug-resistant tuberculosis is delayed in a South African prospective cohort**

*B.J. Sullivan, J. Prvu Bettger, S. Silva, J. Humphreys, C.K. Cunningham, J.E. Farley  
United States*

**High uptake of antiretroviral therapy among HIV-positive TB patients receiving co-located services in Swaziland**

*I. Pathmanathan, M. Pasipamire, S. Pals, E.K. Dokubo, P. Preko, T. Ao, S. Mazibuko, J. Ongole, S. Haumba  
United States*

**Feasibility of using determine-TB LAM test in HIV-infected adults in programmatic conditions**

*S.C. Mathabire, L. Cossa, J. Mpunga, I. Manhiça, I. Amoros Quiles, L. Molfino, E. Szumilin, O. Telnov, H. Huerga  
France*

**MOSY07 HIV Drug Resistance (HIVDR) and Antimicrobial Resistance (AMR): Science and Action**

Symposia Session

**Venue:** Le Grand Amphithéâtre

**Time:** 16:30-18:00

**Co-Chairs:** Meg Doherty, World Health Organization (WHO), Switzerland  
Avelin Aghokeng Fobang, CREMER, Virology laboratory IMPM-IRD, Cameroon

A panel of Ministries of Health representatives, researchers, modellers and policy makers describe the country level evidence leading to the new WHO HIVDR Global Action Plan (GAP) and recommendations for a public health response. This session also investigates the synergies between the HIVDR GAP and the broader AMR agenda. What can we learn from TB and malaria as the HIVDR action plan and AMR country action plans are implemented? Where are the gaps in science and how can researchers fill these gaps?

**Results from the Mexico HIVDR survey leading to country and regional responses**

*S. Avila, Ministry of Health, Mexico*

**Modelling the cost and cost-effectiveness of responses to HIVDR**

*A. Phillips, University College London (UCL), United Kingdom*

**What is the connection between HIVDR and the broader AMR agenda and what is the way forward?**

*D. Pillay, Africa Centre for Population Health, South Africa*

**What can HIVDR programmes learn from MDR-TB and malaria resistance programmes and what is the way forward?**

*M. Robalo, WHO, Congo, Republic of the*

**Round table: what are the science and implementation gaps and where do we go from here?**

**Introduction**

*M. Doherty, World Health Organization (WHO), Switzerland*

**Closing remarks**

**MOSY08 On-demand Oral TDF/FTC for PrEP: Is it an Option?**

Symposia Session

**Venue:** Blue Amphitheater



**Time:** 16:30-18:00

**Co-Chairs:** Sheena McCormack, University College London (UCL), United Kingdom  
Salim Abdool Karim, Centre for the AIDS Programme of Research in South Africa (CAPRISA), South Africa

Oral TDF/FTC is approved for daily PrEP by an increasing number of countries worldwide and is recommended by WHO as an additional prevention tool. Intermittent on-demand, or sex-driven, PrEP has been assessed in a limited number of studies and, although recommended by the European AIDS Clinical Society and French, UK and Canadian guidelines for men who have sex with men (MSM), it is not yet widely accepted as an alternative for daily PrEP. This session reviews the current evidence for on-demand PrEP, from animal models to pharmacokinetics (PK), and summarizes recent data among MSM; while also addressing current knowledge gaps to encourage future research, particularly among heterosexual men and women. The content is targeted at healthcare providers, community advocates, regulators, pharmacologists, researchers in prevention, private and public agencies, and individuals using PrEP and gives participants a better understanding of on-demand PrEP as a viable alternative to daily PrEP.

## **Introduction**

*S.McCormack, University College London (UCL), United Kingdom*

## **Input from animal models**

*W.Heneine, Centers for Disease Control (CDC), United States*

## **Does pharmacology support on demand PrEP?**

*A.Kashuba, University of North Carolina, United States*

## **Review of clinical studies of intermittent PrEP**

*R.Grant, Gladstone Institutes/UCSF, United States*

## **Acceptability and adherence to intermittent sex-driven PrEP**

*T.Holtz, Centers for Disease Control and Prevention (CDC), India*

## **Questions and answers**

*S.McCormack, University College London (UCL), United Kingdom*

## **Closing remarks**

---